 GlaxoSmithKline plc NYSE: GSK and Vir Biotechnology Inc NASDAQ: VIR have announced topline data from COMET-TAIL Phase 3 trial evaluating sotrovimab delivered via Intramuscular IM administration compared to IV administration in high-risk COVID-19 patients. The trial achieved its primary endpoint, demonstrating that IM administration of sotrovimab was non-inferior to intravenous IV administration for the early treatment of mild-to-moderate COVID-19 up to seven days after symptom onset. 